Also called CKD
There are 4,252 papers on chronic kidney disease in aging research: 203 trials and 2,586 observational studies in people, 161 in animals, 9 in cells, 1,130 reviews.
4,252 papers study it1,598 more mention it1,546 findings
635 new papers in 30 daysSee all 5,850 papers on chronic kidney disease
At a glance
Chronic kidney disease is linked with higher mortality, stroke risk and functional decline in human cohorts. In people with heart failure, it is associated with frailty; in people with hypertension but no diabetes or prior stroke, it is linked with cognitive impairment and dementia. Other observational studies link kidney disease with older age, metabolic burden and inflammatory markers.
1,546 findings in 1,076 papers from 2008 to 2026, 263 of them since April 2026
“AAMR increased significantly from 132.0 in 1999 to 216.6 in 2020.”
- Human trial203
- Humans2,586
- Animals161
- Cells9
- In silico120
Interventions
14SGLT2 inhibitors
downin humans4
4 studies
SGLT2 inhibitors
downin humans4
SGLT2 inhibitors decrease chronic kidney disease in humans across diabetic and non-diabetic populations.
“Landmark clinical trials have consistently demonstrated reductions in heart failure hospitalization, chronic kidney disease progression, and cardiovascular mortality across diabetic and non-diabetic populations.”
Reviewacross diabetic and non-diabetic populations
Cardiology in review
SGLT2 inhibitors decrease chronic kidney disease in humans (including in patients without diabetes).
“Randomized trials and meta-analyses show their most consistent benefits are reducing heart failure hospitalization and slowing chronic kidney disease progression, including in patients without diabetes.”
Reviewincluding in patients without diabetes
SGLT2 Inhibitors in the Modern Cardiology Era: Mechanisms, Outcomes, and Clinical Applications
Cardiology in review
SGLT2 inhibitors decrease chronic kidney disease in type 2 diabetes, heart failure, and chronic kidney disease.
“adding SGLT2 inhibitors to RAAS-based therapy reduces heart failure hospitalizations and slows kidney disease progression”
Reviewin type 2 diabetes, heart failure, and chronic kidney disease
Biomedicines
SGLT2 inhibitors protect against chronic kidney disease in people with and without diabetes.
“SGLT2 inhibitors have offered protection against heart failure and chronic kidney disease”
Reviewin people with and without diabetes
Cardiorenal effects of therapies for type 2 diabetes and obesity
The British journal of cardiology
GLP-1 receptor agonists
no changein humans1downin humans1HR 1.26
2 studies
GLP-1 receptor agonists
no changein humans1downin humans1HR 1.26
GLP-1 receptor agonists were not clearly linked with chronic kidney disease in humans (propensity-matched comparison with non-GLP-1 users) (HR 1.26 (95% CI 0.82-1.95)).
“or progression to CKD between the two groups (HR 1.26, 95% CI 0.82-1.95; P = 0.294)”
Humanspropensity-matched comparison with non-GLP-1 users12 monthsn = 1,391
Orphanet journal of rare diseases
GLP-1 receptor agonists protect against chronic kidney disease in humans.
“improving cardiovascular outcomes, and preserving renal function”
Review
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
Reviews in cardiovascular medicine
Aspirin
no changein humans1
1 study
Aspirin
no changein humans1
Aspirin was not clearly linked with chronic kidney disease in humans (Postpartum; aspirin prescription before 16 weeks of gestation).
“No significant associations were observed for incident chronic kidney disease or cardiometabolic morbidity.”
HumansPostpartum; aspirin prescription before 16 weeks of gestationMedian 5-year follow-upfemalesn = 31,042
ESC Congress 2026 abstract
Physical inactivity
no changein humans1HR 1.22
1 study
Physical inactivity
no changein humans1HR 1.22
Physical inactivity was not clearly linked with chronic kidney disease in humans (without depressive symptoms vs physically active without depressive symptoms) (HR 1.22, 95% CI 0.82-1.83).
“1.22 (95% CI: 0.82, 1.83) for physical inactivity without depressive symptoms”
Humanswithout depressive symptoms vs physically active without depressive symptoms
Acta psychologica
Ras inhibitors
downin humans1
1 study
Ras inhibitors
downin humans1
Ras inhibitors decrease chronic kidney disease in four-pillar pharmacotherapy.
“When tailored to the degree of albuminuria and eGFR, this treatment significantly slows the progression of chronic kidney disease and reduces cardiovascular risk.”
Reviewin four-pillar pharmacotherapykidney
Albuminuria for detection of chronic kidney disease: biomarker and therapeutic target
Orvosi hetilap
Alcohol
no changein humans1
1 study
Alcohol
no changein humans1
Alcohol was not clearly linked with chronic kidney disease in humans (adjusted Cox proportional hazards models).
“alcohol intake was not associated with CKD incidence”
Humansadjusted Cox proportional hazards modelsmean 11.7-year follow-upn = 5,369
Scientific reports
Angiotensin-converting enzyme inhibitors
downin humans1
1 study
Angiotensin-converting enzyme inhibitors
downin humans1
Angiotensin-converting enzyme inhibitors protect against chronic kidney disease in patients with stage 3 to 5 chronic kidney disease.
“in patients with stage 3 to 5 chronic kidney disease, limited evidence suggests that ACEIs may confer superior renoprotective benefits.”
Reviewin patients with stage 3 to 5 chronic kidney disease
All in on ARBs: Is it time to fold the ACEIs?
Canadian family physician Medecin de famille canadien
Finerenone
downin humans1
1 study
Finerenone
downin humans1
Finerenone decreases chronic kidney disease in humans (established diabetic chronic kidney disease).
“Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD”
Reviewestablished diabetic chronic kidney disease
Kidney research and clinical practice
Semaglutide
downin reviews1
1 study
Semaglutide
downin reviews1
Semaglutide prevents chronic kidney disease (patients with type 2 diabetes).
“In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD)”
Reviewpatients with type 2 diabetes
Nephrology : what's new in 2025
Revue medicale suisse
Dash diet
downin humans1
1 study
Dash diet
downin humans1
Dash diet protects against chronic kidney disease in humans (CKD prevention and protection).
“both MD and DASH exert significant preventive and protective effects against CKD”
ReviewCKD prevention and protection
Frontiers in nutrition
All 14Fewer
Effects
49Mortality
upin humans6mediatesin humans1no changein humans1+25%OR 1.54
8 studies
Mortality
upin humans6mediatesin humans1no changein humans1+25%OR 1.54
Chronic kidney disease is linked with mortality in humans (indirect effect mediating sex-related difference in TR-associated mortality) (indirect OR 1.54).
“most prominent indirect effects related to chronic kidney disease (CKD; indirect OR 1.54)”
Humansindirect effect mediating sex-related difference in TR-associated mortalityn = 122,501
Sex, comorbidities, and mortality in tricuspid regurgitation: Reassessing risk beyond valve severity
ESC Congress 2026 abstract
Chronic kidney disease is linked with higher mortality in humans (+24.6%).
“age-standardized mortality rate increased by 24.6% to 18.5 per 100,000”
Humans
Medicine
Chronic kidney disease is linked with higher mortality in 2021 (64.03 per 100,000).
“Nearly two-thirds of patients were postmenopausal women, and their age-standardized mortality rate and age-standardized disability-adjusted life-years (DALYs) rate had significantly increased to 64.03 and 1493.31 per 100,000, respectively.”
Humansin 2021females
Chronic kidney disease in women: Global trends and metabolic-cardiovascular associations
Chinese medical journal
Chronic kidney disease is linked with higher mortality in humans with CKD (APC, 2.3 [95% CI, 1.7-3.0]).
“mortality rates increased among women with CKD (APC, 2.3 [95% CI, 1.7-3.0]).”
Humanswith CKDfemales
American journal of kidney diseases : the official journal of the National Kidney Foundation
Chronic kidney disease is linked with higher mortality in patients with chronic heart failure (2.5-fold (28.6% vs. 11.1%)).
“In-hospital mortality was 2.5-fold higher in patients with CKD (28.6% vs. 11.1%; p < 0.001).”
Humansin patients with chronic heart failuren = 2,227
Diseases (Basel, Switzerland)
Chronic kidney disease is linked with higher mortality in humans (coexisting CKD and dementia) (1.03 to 5.92 per 100 000 (AAPC 7.41%)).
“The overall AAMR increased from 1.03 to 5.92 per 100 000 (AAPC 7.41%).”
Humanscoexisting CKD and dementia1999 to 2020n = 170,375
Annals of medicine and surgery (2012)
Chronic kidney disease was not clearly linked with mortality in humans (fragility fractures, eGFR 45-59 ml/min/1.73 m2) (HR 1.01, 95% CI 0.64-1.58).
“but not in the 45-59 ml/min/1.73 m2 group (HR 1.01, 95% CI 0.64-1.58).”
Humansfragility fractures, eGFR 45-59 ml/min/1.73 m2n = 453
Chronic kidney disease and mortality in fragility fracture patients: revisiting GFR thresholds
European geriatric medicine
Chronic kidney disease increases mortality in humans (1.5 million annually).
“1.5 million people annually (one every 20 seconds) die from CKD.”
Review
The updated global burden of chronic kidney disease: one death every 20 seconds
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Physical function
downin humans3
3 studies
Physical function
downin humans3
Chronic kidney disease is linked with worse physical function in humans (CKD stage 3 and 4 compared with healthy controls).
“SPPB, MVIC, and 6MWT performance decreased significantly between HC to CKD stage 3, to CKD stage 4.”
HumansCKD stage 3 and 4 compared with healthy controls
BMC nephrology
Chronic kidney disease is linked with worse physical function in patients with chronic heart failure (p < 0.001).
“A significant difference in the distribution of NYHA functional classes was observed between the groups (p < 0.001), with NYHA class IV being more prevalent in the CKD group”
Humansin patients with chronic heart failuren = 2,227
Diseases (Basel, Switzerland)
Chronic kidney disease is linked with worse physical function in humans (431.2 ± 112.9 vs. 484.1 ± 99.4 m).
“poorer endurance (6MWT: 431.2 ± 112.9 vs. 484.1 ± 99.4 m)”
Humansmales
Journal of the American Geriatrics Society
Cellular senescence
upin humans1upin rats1
2 studies
Cellular senescence
upin humans1upin rats1
Chronic kidney disease increases cellular senescence in rats.
“A marker of cellular senescence was elevated in cortical osteocytes due to both CKD and aging.”
Animalscortical osteocytes
Older rats had more severe bone changes with kidney disease
Bone
Chronic kidney disease induces cellular senescence in humans.
“Besides, CKD and its comorbid conditions can result in inflammation, oxidative stress, apoptosis, and necrosis, which stimulate premature senescence in multiple body organs.”
Review
Eurasian Journal of Medicine and Oncology
Potent GLP-1-RA initiation
no changein humans1
1 study
Potent GLP-1-RA initiation
no changein humans1
Chronic kidney disease was not clearly linked with potent GLP-1-RA initiation in humans (CKD stages I to IV) (aOR 0.97 (stages I and II), 0.98 (stages III and IV)).
“Chronic kidney disease across stage I to IV was not associated with increased odds of initiation (aOR 0.97 for stage I and II; 0.98 for stage III and IV).”
HumansCKD stages I to IV
Utilization patterns of potent GLP-1-RA among patients with type 2 diabetes in clinical practice
ESC Congress 2026 abstract
Gross domestic product loss
upin silico1
1 study
Gross domestic product loss
upin silico1
Chronic kidney disease increases gross domestic product loss in silico (INT $6.45 trillion (95% CI, INT $5.34–$7.37 trillion)).
“The cumulative GDP loss attributable to CKD from 2025 to 2060 is projected to be INT $6.45 trillion (95% CI, INT $5.34–$7.37 trillion)”
In silico2025–2060
China faces $6.45 trillion kidney disease burden through 2060
Research SquarePreprint
Prevalence
upin silico1
1 study
Prevalence
upin silico1
Chronic kidney disease increases prevalence in silico.
“Age-standardized incidence and mortality rates are projected to remain relatively stable, while prevalence increases substantially.”
In silico2025–2060
China faces $6.45 trillion kidney disease burden through 2060
Research SquarePreprint
Frailty
upin humans1
1 study
Frailty
upin humans1
Chronic kidney disease increases frailty in humans.
“Chronic kidney disease (CKD) is increasingly recognized as a model of accelerated biological aging, characterized by premature cardiovascular disease and frailty.”
Review
Vascular frailty: A new paradigm linking biological aging, gero-nephrology, and vascular medicine
Ageing research reviews
aPWV
upin humans1
1 study
aPWV
upin humans1
Chronic kidney disease is linked with higher aPWV in humans (stage 3b-5 CKD or receiving dialysis).
“aPWV was higher in the CKD group than in controls.”
Humansstage 3b-5 CKD or receiving dialysis
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Variant allele fraction of CHIP-associated mutations
upin humans1
1 study
Variant allele fraction of CHIP-associated mutations
upin humans1
Chronic kidney disease is linked with higher variant allele fraction of CHIP-associated mutations in humans among CHIP-positive participants, compared with healthy controls in the GENIE cohort (7.3% versus 4.4%; P = 0.02).
“the median VAF of CHIP-associated mutations was significantly higher in participants within the KNOW-CKD cohort compared with healthy controls in the GENIE cohort (7.3% versus 4.4%; P = 0.02)”
Humansamong CHIP-positive participants, compared with healthy controls in the GENIE cohort
Clinical journal of the American Society of Nephrology : CJASN
More on Variant allele fraction of CHIP-associated mutations
Clonal hematopoiesis prevalence
upin humans1
1 study
Clonal hematopoiesis prevalence
upin humans1
Chronic kidney disease is linked with higher clonal hematopoiesis prevalence in humans (compared with general population controls in the GENIE cohort) (17% versus 11%; P = 0.04).
“The prevalence of CHIP was significantly higher in the KNOW-CKD cohort than in the GENIE cohort (17% versus 11%; P = 0.04).”
Humanscompared with general population controls in the GENIE cohort
Clinical journal of the American Society of Nephrology : CJASN
All 49Fewer
Upstream
37C-reactive protein
mediatesin humans2
2 studies
C-reactive protein
mediatesin humans2
C-reactive protein is linked with chronic kidney disease in humans (Mediation proportions ≤9.0%, declining to 1.7% for ≥4 components).
“PIV and CRP partially mediated this, but the proportions were small (≤9.0%) and declined with MetS burden (1.7% for ≥4).”
Humansmediation of the association between cumulative metabolic syndrome burden and chronic kidney diseasen = 20,326
Frontiers in endocrinology
C-reactive protein is linked with chronic kidney disease in humans (effect of homocysteine on CKD risk) (15.04%).
“C-reactive protein and erythrocyte sedimentation rate mediating 15.04% and 6.39% of the effect, respectively”
Humanseffect of homocysteine on CKD risk
Journal of inflammation research
Body mass index
mediatesin humans2
2 studies
Body mass index
mediatesin humans2
Body mass index is linked with chronic kidney disease in humans (mediating sulfur microbial diet and CKD) (23.13% of the association).
“BMI explained 23.13% of the association.”
Humansmediating sulfur microbial diet and CKD
Frontiers in nutrition
Body mass index is linked with chronic kidney disease in humans (association of hypothyroidism with incident chronic kidney disease, with obesity).
“Body mass index and obesity partially mediated this effect.”
Humansassociation of hypothyroidism with incident chronic kidney disease, with obesity
The Journal of international medical research
Hypertension duration
no changein humans1
1 study
Hypertension duration
no changein humans1
hypertension duration showed no clear effect on chronic kidney disease in humans.
“Also, we observed no evidence suggesting modification of hypertension duration on intensive SBP treatment effect on kidney events (P for interaction >0.05).”
Human trialaverage follow‐up time 3.17 yearsn = 8,230
Journal of the American Heart Association
hypertension duration showed no clear effect on chronic kidney disease in humans (hypertension) (P for interaction >0.05).
“For kidney events, no treatment interaction effects or significant associations with hypertension duration were observed (P for interaction >0.05).”
Human trialhypertension
Journal of the American Heart Association
Time
no changein humans1downin humans1OR 0.95
1 study
Time
no changein humans1downin humans1OR 0.95
time was not clearly linked with chronic kidney disease in humans among individuals with hypertension.
“No decrease in chronic kidney disease was seen among individuals with hypertension.”
Humansamong individuals with hypertension
Decreasing Prevalence of Chronic Kidney Disease Among U.S. Adults With Diabetes, 1999-2018
AJPM focus
time is linked with lower chronic kidney disease in humans among individuals with diabetes (40.5% to 35.4% (OR 0.95, 95% CI 0.90-0.99)).
“prevalence of chronic kidney disease among individuals with diabetes decreased from 40.5% to 35.4% over 20 years (p=0.02) with a decline of ∼5% during each 4-year period (OR=0.95, 95% CI=0.90, 0.99)”
Humansamong individuals with diabetes20 yearsn = 7,320
Decreasing Prevalence of Chronic Kidney Disease Among U.S. Adults With Diabetes, 1999-2018
AJPM focus
Pan-immune-inflammation value
mediatesin humans1
1 study
Pan-immune-inflammation value
mediatesin humans1
Pan-immune-inflammation value is linked with chronic kidney disease in humans (Mediation proportions ≤9.0%, declining to 1.7% for ≥4 components).
“PIV and CRP partially mediated this, but the proportions were small (≤9.0%) and declined with MetS burden (1.7% for ≥4).”
Humansmediation of the association between cumulative metabolic syndrome burden and chronic kidney diseasen = 20,326
Frontiers in endocrinology
Incident hypertension and/or diabetes mellitus
mediatesin humans1
1 study
Incident hypertension and/or diabetes mellitus
mediatesin humans1
Incident hypertension and/or diabetes mellitus is linked with chronic kidney disease in humans (Indirect pathways all p<0.05).
“incident HTN and/or DM mediated the relationship between noise and CKD (indirect pathways all p<0.05, Figure 1) across noise thresholds.”
HumansPartial mediation of the association between transportation noise and chronic kidney diseaseNoise thresholds of >45, >50, and >55 dBA
Transportation noise linked to new chronic kidney disease
ESC Congress 2026 abstract
Decreasing waist circumference trajectory
no changein humans1HR 0.83
1 study
Decreasing waist circumference trajectory
no changein humans1HR 0.83
decreasing waist circumference trajectory was not clearly linked with chronic kidney disease in humans (compared with stable waist circumference trajectory) (adjusted HR 0.83, 95% CI 0.56-1.23).
“whereas the decreasing trajectory was not (adjusted HR, 0.83; 95% CI, 0.56-1.23).”
Humanscompared with stable waist circumference trajectorymedian follow-up of 11.8 yearsn = 5,429
Association of waist circumference trajectories with incident chronic kidney disease
Kidney research and clinical practice
Visceral adiposity index
no changein humans1OR 1.03
1 study
Visceral adiposity index
no changein humans1OR 1.03
Visceral adiposity index was not clearly linked with chronic kidney disease in humans (high dietary magnesium intake) (OR 1.03, 95% CI 0.96-1.10).
“In contrast, no significant relation was observed among individuals with high dietary magnesium intake (OR = 1.03, 95% CI: 0.96-1.10; P = 0.252).”
Humanshigh dietary magnesium intake
Food & nutrition research
Excess adiposity
no changein humans1
1 study
Excess adiposity
no changein humans1
Excess adiposity was not clearly linked with chronic kidney disease in Korean adults with type 2 diabetes mellitus.
“excess adiposity was associated with increased risk in women but not in men.”
Humansin Korean adults with type 2 diabetes mellitus4 yearsmales
Underweight is linked to higher kidney disease risk in diabetes
Frontiers in endocrinology
INHBC
mediatesin silico1
1 study
INHBC
mediatesin silico1
INHBC mediates chronic kidney disease in silico (association between T2D and kidney disease diagnosis) (1.3% (95% CI 0.85% to 1.9%)).
“circulating INHBC levels mediate 1.3% (95% confidence interval [0.85%, 1.9%]) of the association between T2D and kidney disease diagnosis”
In silicoassociation between T2D and kidney disease diagnosis
Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study
PLoS medicine
All 37Fewer
Associations
479Mortality
upin humans36no changein humans1mixedin humans1+57% mortalityHR 1.174–5.35
38 studies
Mortality
upin humans36no changein humans1mixedin humans1+57% mortalityHR 1.174–5.35
Chronic kidney disease is associated with mortality in humans (Exploratory analysis among individuals undergoing lower limb amputation).
“Exploratory analyses identified chronic kidney disease and heart failure among the comorbidities associated with increased mortality.”
HumansExploratory analysis among individuals undergoing lower limb amputation
Scientific reports
Chronic kidney disease predicts mortality in humans Following ICD implantation (HR 1.81, 95% CI 1.41-2.34; mortality 3.1% in G1 versus 36.8% in G5/ESRD).
“In multivariable analysis, CKD was the strongest independent predictor of mortality (HR 1.81, 95% CI 1.41-2.34, p<0.001)”
HumansFollowing ICD implantationMedian follow-up 2,414 days37% femalesn = 1,662
AHA Scientific Sessions 2026 abstract
Chronic kidney disease is linked with a higher risk of mortality in humans (patients with heart failure and metabolic syndrome; compared with eGFR ≥60) (41% excess mortality risk; adjusted HR 2.14 in eGFR <15).
“CKD overall was associated with 41% excess mortality risk.”
Humanspatients with heart failure and metabolic syndrome; compared with eGFR ≥60
ESC Congress 2026 abstract
Chronic kidney disease is associated with mortality in humans (Patients with NSTEMI; adjusted analysis of individual CKM components) (TAMI HR 1.466; MIMIC-IV HR 1.495).
“Among the individual components, CKD was associated with the highest mortality risk in both cohorts (TAMI cohort HR: 1.466; MIMIC-IV cohort HR: 1.495)”
HumansPatients with NSTEMI; adjusted analysis of individual CKM components10 years
ESC Congress 2026 abstract
Chronic kidney disease is associated with mortality in humans (Heart failure and metabolic syndrome; multivariable adjustment) (eGFR <60: HR 1.55 in men versus 1.62 in women; p-interaction=0.875).
“After multivariable adjustment worsening CKD was similarly associated with mortality in men and women (eGFR <60: HR 1.55 vs 1.62; p-interaction=0.875).”
HumansHeart failure and metabolic syndrome; multivariable adjustmentMedian follow-up 8.89 yearsn = 5,629
ESC Congress 2026 abstract
Chronic kidney disease predicts mortality in humans (HR 1.80, 95% CI 1.32–2.44).
“CKD remained independently associated with mortality (HR 1.80, 95% CI 1.32–2.44).”
Humansn = 2,376
ESC Congress 2026 abstract
Chronic kidney disease predicts mortality in humans Following surgery for traumatic subaxial cervical spinal cord injury.
“Increasing age, male sex, diabetes, heart failure, and chronic kidney disease independently predicted mortality.”
HumansFollowing surgery for traumatic subaxial cervical spinal cord injuryn = 5,477
The journal of spinal cord medicine
Chronic kidney disease is linked with a higher risk of mortality in tuberculosis patients aged < 65 years (adjusted risk ratio 3.78).
“CKD was more strongly associated with mortality below 65 years than at older ages (adjusted risk ratio 3.78 versus 1.75; ratio of risk ratios 2.16, 95% confidence interval 1.67–2.79; P < 0.001).”
Humansin tuberculosis patients aged < 65 years
Research SquarePreprint
Chronic kidney disease is linked with a higher risk of mortality in people with diabetes.
“Mortality declined in people with and without CKD but remained substantially higher among those with CKD.”
Humansin people with diabetes
Diabetes, obesity & metabolism
Chronic kidney disease is associated with mortality in humans (coexisting with lung cancer) (from 0.70 to 1.50 per 100,000 population).
“The overall AAMR increased from 0.70 to 1.50 per 100,000 population, corresponding to an AAPC of 1.29% (95% CI, 0.52–2.20).”
Humanscoexisting with lung cancer1999–2024n = 37,851
Research SquarePreprint
All 39Fewer
Hypertension
upin humans13upin dogs1OR 2.61–12.3
14 studies
Hypertension
upin humans13upin dogs1OR 2.61–12.3
Chronic kidney disease is associated with hypertension in humans (Adults with versus without chronic kidney disease) (OR 4.46, 95% CI 4.30-4.62; prevalence 76.1% versus 41.7%).
“All components were significantly more prevalent with CKD: hypertension (76.1% vs. 41.7%; OR 4.46, 95% CI 4.30-4.62)”
HumansAdults with versus without chronic kidney diseasen = 327,671
AHA Scientific Sessions 2026 abstract
Hypertension is associated with chronic kidney disease in humans (tertiary care internal medicine outpatients) (OR 2.61, 95% CrI 1.96–3.54).
“hypertension (OR 2.61, 95% CrI 1.96 to 3.54)”
Humanstertiary care internal medicine outpatients
BMJ open
Hypertension is linked with a higher risk of chronic kidney disease in humans (adjusted for age, race, and gender in class II and III obesity patients) (OR 12.3).
“The odds ratio for CKD was 12.3 for hypertensives and 4.0 for diabetics, adjusted for age, race, and gender.”
Humansadjusted for age, race, and gender in class II and III obesity patientsn = 202
Nutrition (Burbank, Los Angeles County, Calif.)
Hypertension is linked with a higher risk of chronic kidney disease in patients with type 2 diabetes mellitus (aOR: 1.37, 95% CI: 1.10, 1.70).
“hypertension (aOR: 1.37, 95% CI: 1.10, 1.70)”
Humansin patients with type 2 diabetes mellitus
The Medical journal of Malaysia
Hypertension is linked with a higher risk of chronic kidney disease in humans (globally).
“high blood glucose, hypertension, and obesity were identified as the leading contributors to CKD-related DALYs globally”
Humansglobally
Medicine
Hypertension is associated with chronic kidney disease in humans (p = 0.001).
“hypertension status (p = 0.001) were significantly associated with CKD.”
Humansmalesn = 46,510
MEDICA (International Medical Scientific Journal)
Hypertension is linked with a higher risk of chronic kidney disease in humans.
“Males, older adults, and participants with hypertension or diabetes mellitus were at higher risks.”
Humans
Kidney international reports
Hypertension is linked with a higher risk of chronic kidney disease in humans (national survey) (aOR 2.41 (2.07-2.82)).
“CKD prevalence was highest in northwest Iran, increased significantly with age, with a stronger association observed for low eGFR than albuminuria, and was associated with hypertension (aOR 2.41 (2.07-2.82))”
Humansnational surveyn = 17,607
BMJ open
Hypertension is associated with chronic kidney disease in clinic-based cohort in Sudan (14.3% exhibited GFR <60 mL/min/1.73 m2).
“Hypertension was detected in 8.2% of the subjects, among whom 14.3% exhibited a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2.”
Humansin clinic-based cohort in Sudan
Common Risk Factors Associated With Chronic Kidney Disease in Sudan: A Pilot Study
Cureus
Hypertension is associated with chronic kidney disease in humans (tribal communities).
“CKD was positively associated with older age, hypertension, diabetes, lower education, and low body mass index (BMI).”
Humanstribal communitiesn = 2,029
CKD in Indigenous Populations in Kerala, India
Kidney international reports
All 14Fewer
Diabetes mellitus
upin humans9OR 3.03–4
9 studies
Diabetes mellitus
upin humans9OR 3.03–4
Diabetes mellitus is associated with chronic kidney disease in humans (Fulni-ô Indigenous adults; multivariable adjustment) (adjusted OR 3.03; 95% CI 1.53–5.90).
“only age ≥ 60 years (adjusted OR 3.58; 95% CI 2.03–6.27) and diabetes (adjusted OR 3.03; 95% CI 1.53–5.90) remained independently associated with the composite outcome.”
HumansFulni-ô Indigenous adults; multivariable adjustmentn = 569
BMC nephrology
Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans (adjusted for age, race, and gender in class II and III obesity patients) (OR 4.0).
“The odds ratio for CKD was 12.3 for hypertensives and 4.0 for diabetics, adjusted for age, race, and gender.”
Humansadjusted for age, race, and gender in class II and III obesity patientsn = 202
Nutrition (Burbank, Los Angeles County, Calif.)
Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans.
“Males, older adults, and participants with hypertension or diabetes mellitus were at higher risks.”
Humans
Kidney international reports
Chronic kidney disease is associated with diabetes mellitus in adults with hypertension (AOR 1.74, 95% CI 1.42-2.14).
“chronic renal disease (1.74, 1.42-2.14)”
Humansin adults with hypertension
Scientific reports
Diabetes mellitus is associated with chronic kidney disease in clinic-based cohort in Sudan (22.2% showed GFR <60 mL/min/1.73 m2).
“Among the 15.8% of diabetic individuals, 22.2% showed a GFR of <60 mL/min/1.73 m2.”
Humansin clinic-based cohort in Sudan
Common Risk Factors Associated With Chronic Kidney Disease in Sudan: A Pilot Study
Cureus
Diabetes mellitus is associated with chronic kidney disease in humans (tribal communities).
“CKD was positively associated with older age, hypertension, diabetes, lower education, and low body mass index (BMI).”
Humanstribal communitiesn = 2,029
CKD in Indigenous Populations in Kerala, India
Kidney international reports
Diabetes mellitus is linked with a higher risk of chronic kidney disease in humans (hypertensive patients) (AHR 3.08, 95% CrI 2.01-9.54).
“diabetes mellitus (AHR = 3.08; 95% CrI: 2.01-9.54), and proteinuria positivity (AHR = 2.85; 95% CrI: 1.48-5.55) were significant predictors of the incidence of CKD”
Humanshypertensive patientsn = 408
PloS one
Diabetes mellitus is associated with chronic kidney disease in humans (Bangladesh).
“identified several factors associated with CKD in Bangladesh, such as diabetes mellitus, hypertension, lower economic and educational status, older age, and high dietary salt intake.”
ReviewBangladesh
Scientific reports
Diabetes mellitus raises the risk of chronic kidney disease in humans.
“The major causes of CKD include diabetes mellitus, hypertension, glomerulonephritis, and genetic or hereditary kidney disorders.”
Review
CHRONIC KIDNEY DISEASE: GLOBAL BURDEN, RISK FACTORS, AND THERAPEAUTIC PERSPECTIVES
Indian Journal of Health Care Medical & Pharmacy Practice
Cardiovascular disease
upin humans9OR 1.5–2.04
9 studies
Cardiovascular disease
upin humans9OR 1.5–2.04
Chronic kidney disease is linked with a higher risk of cardiovascular disease in humans (multivariable logistic regression) (aOR 5.0).
“Independent correlates included CKD (aOR 5.0)”
Humansmultivariable logistic regressionn = 307
medRxivPreprint
Chronic kidney disease is associated with cardiovascular disease in humans (independent of age and sex, adults with uncontrolled hypertension) (adjusted OR 1.5 (1.1-1.9)).
“have higher prevalence of any cardiovascular disease (CVD, 1.5 [1.1-1.9])”
Humansindependent of age and sex, adults with uncontrolled hypertension
AHA Scientific Sessions 2025 abstract
Cardiovascular disease is linked with a higher risk of chronic kidney disease in humans (compared to the healthy heart type) (OR = 2.04, 95% CI: 1.61-2.57).
“while the cardiovascular type increased by 104% (OR = 2.04, 95% CI: 1.61-2.57)”
Humanscompared to the healthy heart type
BMC public health
Chronic kidney disease is associated with cardiovascular disease in humans.
“In CKD, cardiovascular risk progressively increases as kidney function declines.”
Review
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
Chronic kidney disease raises the risk of cardiovascular disease in humans.
“CKD is a key risk factor, mediator and therapeutic target to reduce CVD burden.”
Review
The therapeutic approach to cardiovascular-kidney-metabolic syndrome
Nature reviews. Nephrology
Chronic kidney disease raises the risk of cardiovascular disease in older adults.
“Chronic kidney disease (CKD) is a progressive condition that increases the risk of cardiovascular disease, end-stage kidney disease and premature death.”
Reviewin older adults
Prevent chronic kidney disease and its complications in older adults with a stepwise approach
Drugs & Therapy Perspectives
Chronic kidney disease raises the risk of cardiovascular disease in chronic kidney disease.
“Cardiovascular disease (CVD), which can manifest as coronary artery disease (CAD), stroke, heart failure (HF), arrhythmias, and sudden cardiac death, is more likely to develop in patients with chronic kidney disease (CKD).”
Reviewin chronic kidney disease
Current Appraisal and Gaps in Knowledge in Cardio-Kidney Metabolic Syndrome Definition
International journal of molecular sciences
Chronic kidney disease raises the risk of cardiovascular disease in humans.
“people with CKD are more likely to die from CVD than progress to end-stage kidney disease.”
Review
Chronic kidney disease screening to reduce cardiovascular risk: a call to action
American journal of preventive cardiology
Chronic kidney disease raises the risk of cardiovascular disease in CKD.
“Chronic kidney disease (CKD) substantially increases cardiovascular risk, with endothelial dysfunction as its central pathological mechanism.”
Reviewin CKD
Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease
Diabetes/metabolism research and reviews
Frailty
upin humans8+57%OR 4.25
8 studies
Frailty
upin humans8+57%OR 4.25
Chronic kidney disease is associated with frailty in humans (adults aged ≥ 40 years) (OR 4.25, 95% CI 1.62–11.10).
“chronic kidney disease (4.25 [1.62;11.10]) were associated with frailty”
Humansadults aged ≥ 40 yearsn = 5,296
Multiple chronic illnesses common in adults at five African sites
Research SquarePreprint
Frailty is linked with a higher risk of chronic kidney disease in humans (HR 2.75 (95% CI: 2.61, 2.89)).
“frailty compared to robust individuals were 1.64 (95% CI: 1.59, 1.69) and 2.75 (95% CI: 2.61, 2.89), respectively.”
Humans
International urology and nephrology
Frailty is linked with a higher risk of chronic kidney disease in humans (multivariate model) (HR 1.606 (95% CI, 1.474-1.749, p < 0.001)).
“Compared with non-frailty, the hazard ratio (HR) for new-onset CKD in prefrailty and frailty was 1.143 (95% CI, 1.090-1.199, p < 0.001) and 1.606 (95% CI, 1.474-1.749, p < 0.001)”
Humansmultivariate modelmedian follow-up of 12.9 yearsn = 214,502
Longitudinal Study of Frailty Phenotype in Relation to Chronic Kidney Disease Incidence
Journal of cachexia, sarcopenia and muscle
Chronic kidney disease is associated with frailty in humans (pre-dialysis chronic kidney disease) (57.07%).
“Over half (57.07%) of the participants were rated as frail, with assignment to the frail group significantly influenced by age (p < .001) and CKD severity (p = .008).”
Humanspre-dialysis chronic kidney diseasen = 191
Hu li za zhi The journal of nursing
Chronic kidney disease is associated with frailty in humans (15.2% in robust to 29.0% in frail (P < 0.001)).
“The prevalence of chronic kidney disease (CKD) increased across frailty classes from 15.2% in robust to 29.0% in frail individuals (P < 0.001).”
Humansn = 1,183
Journal of nephrology
Chronic kidney disease is associated with frailty in humans (CKD stages G3-G5 by CKD-EPI) (>50%).
“Over 50% of CKD patients fell into frail phenotypes (Senescent Nephropathy or Frailty Aged Kidney)”
HumansCKD stages G3-G5 by CKD-EPIn = 58,611
International urology and nephrology
Chronic kidney disease is associated with frailty in elderly patients.
“elderly chronic kidney disease (CKD) patients have emerged as a distinct population at a high risk of renal fibrosis progression and poor prognosis.”
Reviewin elderly patients
Common mechanisms and intervention strategies for chronic kidney disease and frailty in older adults
Chinese Journal of Geriatrics
Chronic kidney disease is associated with frailty in humans (chronic kidney disease).
“Frailty in chronic kidney disease (CKD) is increasingly recognized as a manifestation of accelerated biological aging, characterized by systemic impairments that extend beyond the musculoskeletal domain.”
Reviewchronic kidney disease
Biological & pharmaceutical bulletin
Sarcopenia
upin humans8OR 2.52–4.51
8 studies
Sarcopenia
upin humans8OR 2.52–4.51
Chronic kidney disease is associated with sarcopenia in humans (CKD stages 3–5) (OR = 2.520).
“CKD stages 3-5 (OR = 2.520)”
HumansCKD stages 3–5malesn = 172
BMC geriatrics
Chronic kidney disease is associated with sarcopenia in humans (non-dialysis CKD stages G4-5 vs healthy controls) (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]).
“The prevalence of sarcopenia (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]), osteoporosis (21.7% vs. 10.1%; OR 2.44 [1.25-4.99]), and osteosarcopenia (8.7% vs 1.4%; OR 6.44 [1.39-60.4]) were higher in patients with CKD compared to controls.”
Humansnon-dialysis CKD stages G4-5 vs healthy controls
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Sarcopenia is linked with a higher risk of chronic kidney disease in humans (patients with MASLD) (aHR 1.41, 95% CI 1.12-1.77).
“the adjusted hazard ratio (aHR) for incident CKD in participants with sarcopenia compared to those without was 1.41 (95% CI: 1.12-1.77)”
Humanspatients with MASLDn = 19,867
The journal of nutrition, health & aging
Chronic kidney disease is linked with a higher risk of sarcopenia in humans (P < 0.01).
“Chronic kidney disease demonstrated a persistent and statistically significant association with elevated sarcopenia risk throughout the entire study period (P < 0.01).”
Humans
Archives of gerontology and geriatrics
Chronic kidney disease is associated with sarcopenia in humans (highest in advanced stages and among patients receiving renal replacement therapy) (5–62 % prevalence).
“Sarcopenia is reported in 5–62 % of patients with CKD, with the highest prevalence observed in advanced stages and among those receiving renal replacement therapy.”
Reviewhighest in advanced stages and among patients receiving renal replacement therapy
Perm Medical Journal
Chronic kidney disease raises the risk of sarcopenia in humans.
“Chronic kidney disease (CKD) is a condition associated with accelerated aging that contributes to disturbances in nutritional and functional status, thereby predisposing patients, especially whose with end-stage kidney disease, to an increased risk of sarcopenia.”
Review
Nephrology and Dialysis
Chronic kidney disease is associated with sarcopenia in humans (chronic kidney disease).
“A distinctive yet underappreciated feature of CKD-associated frailty is its triple burden-the co-existence of sarcopenia, bone fragility, and cognitive impairment.”
Reviewchronic kidney disease
Biological & pharmaceutical bulletin
Chronic kidney disease is associated with sarcopenia in CKD patients.
“The prevalence of sarcopenia is significantly higher in CKD patients and increases as kidney function deteriorates.”
Reviewin CKD patients
Association between chronic kidney disease and sarcopenia and emerging treatment strategies
Frontiers in nutrition
Metabolic dysfunction-associated steatotic liver disease
upin humans7HR 1.36–1.64
7 studies
Metabolic dysfunction-associated steatotic liver disease
upin humans7HR 1.36–1.64
Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (HR 1.64, 95% CI 1.45–1.85).
“and MASLD with incident CKD (HR = 1.64, 95% CI = 1.45-1.85; both P < 0.001)”
Humansn = 438,126
Kidney disease linked to metabolic fatty liver disease both ways
Nutrition, metabolism, and cardiovascular diseases : NMCD
Chronic kidney disease is associated with metabolic dysfunction-associated steatotic liver disease in humans (HR 1.36, 95% CI 1.26–1.48).
“CKD was associated with incident MASLD (HR = 1.36, 95% CI = 1.26-1.48)”
Humansn = 462,516
Kidney disease linked to metabolic fatty liver disease both ways
Nutrition, metabolism, and cardiovascular diseases : NMCD
Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (OR 2.47 (95% CI 1.76-3.47)).
“MASLD was associated with CKD (adjusted OR, 2.47; 95% CI, 1.76-3.47; p<0.001).”
Humans
Frontiers in endocrinology
Metabolic dysfunction-associated steatotic liver disease predicts chronic kidney disease in humans (FLI-defined lean MASLD).
“FLI-defined lean MASLD, characterized by severe metabolic abnormalities, predicted a higher incident CKD risk”
HumansFLI-defined lean MASLD
International urology and nephrology
Metabolic dysfunction-associated steatotic liver disease is linked with a higher risk of chronic kidney disease in UK Biobank participants.
“While non-lean MASLD consistently increased CKD risk”
Humansin UK Biobank participants
International urology and nephrology
Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans (meta-analysis) (OR 1.19 [1.08-1.31]).
“NAFLD: OR 1.19 [1.08-1.31], RR 1.66 [1.45-1.91], HR 1.43 [1.31-1.55]; MASLD: HR 1.34 [1.08-1.67]”
Humansmeta-analysis
Nutrition & diabetes
Metabolic dysfunction-associated steatotic liver disease raises the risk of chronic kidney disease in humans.
“MASLD increases the risk of cardiovascular and renal complications mainly through shared mechanisms”
Review
Science China. Life sciences
Metabolic dysfunction-associated steatotic liver disease is associated with chronic kidney disease in humans.
“The risk of developing CVD and CKD is considerably elevated in patients with MASLD.”
Review
Reviews in endocrine & metabolic disorders
Metabolic dysfunction-associated steatotic liver disease raises the risk of chronic kidney disease in humans.
“Studies consistently demonstrate a higher prevalence of CKD among patients with MASLD, with greater risk in those with advanced disease such as metabolic dysfunction-associated steatohepatitis and fibrosis.”
Review
Kidney international reports
More on Metabolic dysfunction-associated steatotic liver disease
Obesity
upin humans7OR 1.46
7 studies
Obesity
upin humans7OR 1.46
Obesity is associated with chronic kidney disease in humans (Ghanaian clinic attendees) (aORs 7–8 for Obese I/II).
“Obesity was the strongest independent predictor of CKD (aORs:7–8 for Obese I/II).”
HumansGhanaian clinic attendeesn = 203
PloS one
Chronic kidney disease is associated with obesity in humans (Adults with versus without chronic kidney disease; obesity defined as BMI ≥30 kg/m2) (OR 1.46, 95% CI 1.41-1.51; prevalence 42.1% versus 33.3%).
“obesity (42.1% vs. 33.3%; OR 1.46, 95% CI 1.41-1.51; all p < 0.001)”
HumansAdults with versus without chronic kidney disease; obesity defined as BMI ≥30 kg/m2n = 327,671
AHA Scientific Sessions 2026 abstract
Obesity is linked with a higher risk of chronic kidney disease in hypertensive patients (AHR 2.56, 95% CI 1.63-4.01).
“obesity (AHR = 2.56, 95%CI: 1.63-4.01), and high triglyceride levels (AHR = 1.72, 95%CI: 1.03-2.91) were significant predictors of rapid progression of chronic kidney disease”
Humansin hypertensive patients
PloS one
Obesity is linked with a higher risk of chronic kidney disease in humans (national survey) (aOR 1.94 (1.59-2.36)).
“obesity (1.94 (1.59-2.36))”
Humansnational surveyn = 17,607
BMJ open
Obesity raises the risk of chronic kidney disease in humans.
“Obesity is an important risk factor for chronic kidney disease (CKD)”
Review
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Obesity raises the risk of chronic kidney disease in humans.
“Additional risk factors such as obesity, aging, cardiovascular diseases, and exposure to nephrotoxic agents further contribute to the growing burden of the disease.”
Review
CHRONIC KIDNEY DISEASE: GLOBAL BURDEN, RISK FACTORS, AND THERAPEAUTIC PERSPECTIVES
Indian Journal of Health Care Medical & Pharmacy Practice
Obesity raises the risk of chronic kidney disease in humans (chronic kidney disease).
“Excess weight not only increases CKD risk but also heightens the risk for heart failure, sleep apnea, steatotic liver disease, osteoarthritis”
Reviewchronic kidney disease
Obesity in CKD: Core Curriculum 2026
American journal of kidney diseases : the official journal of the National Kidney Foundation
Type 2 diabetes
upin humans7OR 4.44
7 studies
Type 2 diabetes
upin humans7OR 4.44
Chronic kidney disease is associated with type 2 diabetes in humans (Adults with versus without chronic kidney disease) (OR 4.44, 95% CI 4.30-4.59; prevalence 42.1% versus 14.1%).
“T2DM (42.1% vs. 14.1%; OR 4.44, 95% CI 4.30-4.59)”
HumansAdults with versus without chronic kidney diseasen = 327,671
AHA Scientific Sessions 2026 abstract
Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans (type 2 diabetes mellitus) (aOR 1.80, 95% CI 1.40–2.31).
“T2DM (aOR 1.80, 95% CI 1.40–2.31) were independently associated with CKD”
Humanstype 2 diabetes mellitus
Aging Medicine and Healthcare
Type 2 diabetes is linked with a higher risk of chronic kidney disease in people with overweight or obesity without CKD or HF at baseline (~2-3-fold).
“Having T2D at baseline increased the 5-year risk of developing CKD by ~2-3-fold, and HF by ~1.5-fold.”
Humansin people with overweight or obesity without CKD or HF at baseline5-year risk
ADA Scientific Sessions 2026 abstract
Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans among individuals with hypertension (HR 2.944, 95% CI 2.760–3.139, P < 0.001).
“those with coexisting type 2 diabetes (E11) had a significantly higher risk of developing CKD (N18) compared to those with atrial fibrillation (I48) or chronic ischaemic heart disease (I25) (HR = 2.944”
Humansamong individuals with hypertension
Scientific reports
Type 2 diabetes is associated with chronic kidney disease in humans (Mendelian randomization).
“genetically predicted metabolic factors-including body mass index (BMI), waist circumference, type 2 diabetes, systolic and diastolic blood pressure, triglycerides, and high-density lipoprotein cholesterol-were significantly associated with an increased CKD risk.”
HumansMendelian randomization
Nutrition & diabetes
Type 2 diabetes is linked with a higher risk of chronic kidney disease in humans (confirmed undiagnosed diabetes) (HR 1.33, 95% CI 1.02-1.73).
“Confirmed undiagnosed diabetes was further associated with incident CKD (1.33 [1.02-1.73])”
Humansconfirmed undiagnosed diabetesover 10 yearsn = 6,712
Journal of diabetes research
Type 2 diabetes raises the risk of chronic kidney disease in humans (patients with type 2 diabetes).
“Diabetes is also a major risk factor for chronic kidney disease, which in turn, is associated with an elevated risk of cardiovascular disease.”
Reviewpatients with type 2 diabetes
Why and how should the cardiovascular risk of patients with type 2 diabetes be assessed ?
La Revue du praticien
Cellular senescence
upin reviews4upin humans2
6 studies
Cellular senescence
upin reviews4upin humans2
Chronic kidney disease is associated with cellular senescence.
“CKD is characterized by the presence of senescent tubular epithelial cells in increasing numbers in association with the injury of the nephrons”
Reviewkidney
Natural Resources for Human Health
Cellular senescence is associated with chronic kidney disease.
“Cellular senescence, which represents a state of irreversible cell-cycle arrest accompanied by functional deterioration, is closely associated with AKI, CKD, and RCC.”
Review
Cellular Senescence in Kidney Diseases: From Bench to Clinic
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Cellular senescence raises the risk of chronic kidney disease in humans.
“Senescence predisposes not only to chronic diseases (including CKD) but also acute processes (including AKI).”
Review
The Aging Kidney and Acute Kidney Injury
Journal of the American Society of Nephrology : JASN
Cellular senescence raises the risk of chronic kidney disease.
“inflammaging and cellular senescence contribute to chronic kidney disease (CKD) and impaired regeneration”
Reviewkidney
Cells
Cellular senescence raises the risk of chronic kidney disease.
“The bidirectional interplay between impaired autophagy and cellular senescence exacerbates renal tubular atrophy, glomerulosclerosis, and interstitial fibrosis, thereby promoting CKD progression and maladaptive repair following AKI.”
Review
Autophagy-senescence interplay in kidney disease: mechanistic insights and therapeutic potential
Molecular biology reports
Cellular senescence is associated with chronic kidney disease in humans.
“age-related kidney disease, the counterpart of healthy aging kidney, is closely related to cellular and immune senescence”
Review
Healthy aging and aging-related kidney diseases: lessons from centenarians
Clinical kidney journal
All 479Fewer
Trial sponsors
Company17 trialsPhase 415,281 people
Company15 trialsPhase 410,301 people
Company11 trialsPhase 46,521 people
Company8 trialsPhase 49,143 people
Novartis Pharmaceuticals Corporation
Company5 trialsPhase 42,531 people
Company5 trialsPhase 4824 people
Company1 trialPhase 4374 people
Company1 trialPhase 4296 people
Funding
196 grants since 2016National Institute of Diabetes and Digestive and Kidney Diseases$78.4MJapan Society for the Promotion of Science¥265MUS Department of Veterans Affairs
National Heart, Lung, and Blood InstituteUniversity of Colorado, Denver$75.6K2025–2027
National Institute of Diabetes and Digestive and Kidney DiseasesHealthPartners Institute$1.5M2026–2028
National Institute on AgingUniversity of Pennsylvania$197K2026–2031
National Heart, Lung, and Blood InstituteDuke University$778K2025–2030
Promoting Evidence-Based Chronic Kidney Disease Care among Hispanics/Latinos with Type 2 Diabetes
National Institute of Diabetes and Digestive and Kidney DiseasesDuke University$179K2026–2031
National Heart, Lung, and Blood InstituteBaylor College of Medicine$117K2022–2027
NIH Office of the DirectorUniversity of Florida$2M2025–2027
Multi-Omics and Chronic Kidney Disease: Correlation with Histology
National Institute of Diabetes and Digestive and Kidney DiseasesNew York University School of Medicine$666K2016–2027
Role of Senescence in Podocyte Biology and Progression of CKD
National Institute of Diabetes and Digestive and Kidney DiseasesYale University$624K2026–2030
Chronic Kidney Disease Prognosis Consortium (CKD-PC)
National Institute of Diabetes and Digestive and Kidney DiseasesNew York University School of Medicine$1.7M2023–2028
How this record changed
Summary rewritten as its findings changed.
As it read before
A human cohort links chronic kidney disease with worsening physical function and cognition; other observational studies associate it with higher mortality. In a heart-failure cohort, it is associated with incident frailty at age 70 or younger, but shows no clear link at 82 or older. Observational studies also link kidney disease with older age, diabetes, and metabolic syndrome.
Summary rewritten as its findings changed.
As it read before
Accelerated biological aging is associated with higher chronic kidney disease risk in a human cohort; chronic kidney disease is also linked with functional decline and higher mortality. Human studies link it with dementia in people with diabetes or with hypertension without diabetes or prior stroke. In heart failure, its association with incident frailty varies by age, with no clear link at 82 or older.
Summary rewritten as its findings changed.
As it read before
Human cohorts associate chronic kidney disease with functional decline, cognitive decline and higher mortality, and associate biological-age acceleration with subsequent chronic kidney disease. A study links sarcopenia to kidney disease in people with metabolic dysfunction-associated steatotic liver disease, while another associates moderate or vigorous physical activity with lower kidney disease risk in people with hypertension.
Summary rewritten as its findings changed.
As it read before
Chronic kidney disease is associated with cognitive decline, dementia, and worsening functional limitations in human cohorts. Human studies also link it to biological-age acceleration, increased epigenetic age estimates in patients with CKD or end-stage renal disease, and senescent T cells in predialysis patients.
Summary rewritten as its findings changed.
As it read before
Human cohorts associate chronic kidney disease with dementia in people with diabetes and mortality in patients hospitalized for heart failure. A preprint links it to frailty in adults aged 40 or older; human studies also associate older age and hypertension with chronic kidney disease.